Targeted Intra-arterial Gemcitabine vs. Continuation of IV Gemcitabine Plus Nab-Paclitaxel Following Induction With Sequential IV Gemcitabine Plus Nab-Paclitaxel and Radiotherapy for Locally Advanced Pancreatic Cancer (LAPC).
The study is a multi-center, un-blinded, randomized control study of subjects with locally advanced pancreatic adenocarcinoma which is unresectable.
Location: SIMR (Sacramento/Valley Area)
Please contact: SIMR@sutterhealth.org about TIGeR-PaC Study
Anthony T Pu, Radiation Oncologist, Sivakumar Reddy, M.D., Henal Patel, M.D., Carlin R Hauck, Radiation Oncologist, Charlotte D Kubicky, Radiation Oncologist, Vijay Suhag, M.D., Benjamin Coombs, D.O., Brian K. Kim, M.D, Hubert Y Pan, Radiation Oncologist, Christopher Jones, MD, Aria Sasaki, M.D., Deepti Behl, MD, Jasdeepa Nagi, M.D.